Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAPULCO: Prasugrel vs High-Dose Clopidogrel in ACS
NCT00385944Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2007
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of prasugrel in acute coronary syndrome (ACS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Maximum Platelet Aggregation to 20 Micromolar Adenosine Diphosphate at 14 days. Started Mar 2007; status: completed.
02
Drugs
prasugrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00385944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385944.